公开(公告)号：US20200377509A1

公开(公告)日：2020-12-03

申请号：US16497141

申请日：2018-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  SCOHIA PHARMA, INC

Inventor： Seiji MIWATASHI ,  Yasufumi MIYAMOTO ,  Koji WATANABE ,  Yayoi NAKAYAMA ,  Yuko HITOMI ,  Jumpei AIDA ,  Nobuyuki TAKAKURA ,  Hideki FURUKAWA ,  Naoyoshi NOGUCHI ,  Yasuhiro HIRATA ,  Shizuo KASAl ,  Toshitake KOBAYASHI ,  Tsuyoshi MAEKAWA ,  Satoshi SASAKI ,  Shigemitsu MATSUMOTO

IPC: C07D491/052 ,  C07D401/12 ,  C07D401/14 ,  C07D211/22

Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.

公开(公告)号：US20200039957A1

公开(公告)日：2020-02-06

申请号：US16499432

申请日：2018-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Seiji MIWATASHI ,  Yasufumi MIYAMOTO ,  Koji WATANABE ,  Yayoi NAKAYAMA ,  Yuko HITOMI ,  Jumpei AIDA ,  Nobuyuki TAKAKURA ,  Hideki FURUKAWA ,  Naoyoshi NOGUCHI ,  Yasuhiro HIRATA ,  Kazuaki TAKAMI ,  Norihito TOKUNAGA ,  Tomohiro OKAWA ,  Akita SHIBUYA ,  Shizuo KASAl ,  Toshitake KOBAYASHI ,  Tsuyoshi MAEKAWA

IPC: C07D401/12 ,  C07D211/22 ,  C07D401/14 ,  C07C59/72 ,  C07D213/64 ,  C07D401/10 ,  C07D413/10

Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.